Afabicin  (Synonyms: Debio 1450; AFN-1720)

Afabicin (Debio 1450) is the proagent of Debio1452, specifically targeting staphylococci without significant activity against other Gram-positive or Gram-negative species. Debio1452 is an inhibitor FabI, an enzyme critical to fatty acid biosynthesis in staphylococci.

FabI, Bacterial^[1]

Afabicin (Debio1450) is the prodrug of Debio1452, specifically targeting staphylococci without significant activity against other Gram-positive or Gram-negative species. Debio1452 inhibits FabI, an enzyme critical to fatty acid biosynthesis in staphylococci. Debio1452 is highly active against staphylococci isolates, with MIC₅₀ and MIC₉₀ values of 0.015 μg/mL and 0.12 μg/mL, respectively. Debio1452 also inhibits S. aureus, with MICs of ≤0.12 μg/mL and MIC₅₀ and MIC₉₀ values of 0.004 μg/mL and 0.008 μg/mL, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

485.43

Solid

C₂₃H₂₄N₃O₇P

1518800-35-5

O=P(O)(O)OCN1C2=NC=C(/C=C/C(N(C)CC(OC3=CC=CC=C43)=C4C)=O)C=C2CCC1=O

Room temperature in continental US; may vary elsewhere.

• [1]. Flamm RK, et al. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. Antimicrob Agents Chemother. 2015 May;59(5):2583-7.  [Content Brief]